What Researchers Did
Researchers reviewed existing clinical trials to assess the long-term effectiveness of various treatments for dry mouth caused by radiation therapy in head and neck cancer patients.
What They Found
The review included 23 trials from an initial 2193 studies, focusing on interventions like pilocarpine (3 trials), amifostine (11 trials), and submandibular gland transfer (5 trials). Pilocarpine, cevimeline, and amifostine showed improvement in xerostomia but were associated with toxicity. Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) offered similar efficacy with fewer side effects, while hyperbaric oxygen was evaluated in one trial.
What This Means for Canadian Patients
Canadian patients suffering from radiation-induced dry mouth have several treatment options, though each comes with its own benefits and drawbacks, such as side effects or the need for surgery. This review highlights that while some medications can help, newer approaches like ALTENS may offer relief with fewer adverse effects. Patients should discuss these options with their healthcare providers to find the most suitable long-term management strategy for their specific needs.
Canadian Relevance
The study authors are not identified as Canadian, and the study itself is a review, not a Canadian-specific trial. However, radiation-induced xerostomia is a Health Canada-recognized indication for which hyperbaric oxygen therapy is sometimes considered, as noted in the review.
Study Limitations
This review is limited by the small number of trials available for some interventions, such as hyperbaric oxygen, which was only represented by one study.